Abstract: The subject-matter of the present application concerns oleylcysteineamide (OCA) and OCA derivatives as active agents and their use in the treatment of inflammatory disorders as well as in treating skin whitening.

Abstract: The present disclosure provides self-emulsifying drug delivery systems for delivery of lipophilic compounds, compositions, kits and unit dosage forms thereof, as well as processes for their preparation.

Abstract: The invention generally concerns a novel class of CB 1 receptor binding molecules and uses thereof.

Abstract: A novel platform for manufacturing storage stable and effective drug delivery systems.

Abstract: An ophthalmic composition useful for the treatment of bacterial eye infections is provided. The ophthalmic composition includes the suspension of particles of active anti-bacterial agent in a gelled matrix.

Abstract: Provided is a nanoparticle associated with a plurality of oleylcysteineamide (OCA) molecules for a variety of therapeutic applications. At least a portion of the OCA molecules may be associated with at least one therapeutic agent or at least one non-active agent. Also provided is a drug delivery agent including at least one nanoparticle associated with a plurality of OCA molecules. At least a portion of the OCA molecules is associated with at least one therapeutic agent or at least one or non-active agent. Also provided is a method of delivering a drug to a subject. The method includes administering the drug delivery agent (associated with the drug) to the subject.

Abstract: Provided are Pt (IV) lipophilic derivatives for improved drug performance in cancer therapy, as well as nanocarriers including the same.

Abstract: Provided is a nanoparticle including a water-soluble protein, a glucan and a hydrophilic active agent, the glucan being at least partially cross-linked by a metaphosphate.

Abstract: Provided are Pt (IV) lipophilic derivatives for improved drug performance in cancer therapy, as well as nanocarriers including the same.

Abstract: The present invention relates to a poly(lactic glycolic) acid (PLGA) nanoparticle associated with therapeutic agents for a variety of therapeutic applications.

Abstract: Provided is a nanoparticle including a water-soluble protein, a glucan and a hydrophilic active agent, the glucan being at least partially cross-linked by a metaphosphate.

Abstract: The present invention makes use of a unique methodology of double nano-encapsulation for protecting and controlling the release of active agents, either hydrophobic or hydrophilic, from stable nanoparticles of opposite characteristics. The protection of the active agent was achieved by loading the agent to be protected, into nanocarriers, which were subsequently encapsulated into sub-micron nanoparticles. The sub-micron nanoparticles formation has been successfully achieved by the use of novel nanospray techniques.

Abstract: The present invention makes use of a unique methodology of double nano-encapsulation for protecting and controlling the release of active agents, either hydrophobic or hydrophilic, from stable nanoparticles of opposite characteristics. The protection of the active agent was achieved by loading the agent to be protected, into nanocarriers, which were subsequently encapsulated into sub-micron nanoparticles. The sub-micron nanoparticles formation has been successfully achieved by the use of novel nano spray techniques.

Abstract: The present disclosure provides controlled-release delivery systems for oral delivery of active agents, e.g. lopinavir, comprising micro-particulated with enhanced oral bioavailability and efficacy, which may be used for treating HIV.

Abstract: The present invention relates to a poly(lactic glycolic) acid (PLGA) nanoparticle associated with therapeutic agents for a variety of therapeutic applications.

Abstract: The present invention makes use of a unique methodology of double nano-encapsulation for protecting and controlling the release of active agents, either hydrophobic or hydrophilic, from stable nanoparticles of opposite characteristics. The protection of the active agent was achieved by loading the agent to be protected, into nanocarriers, which were subsequently encapsulated into sub-micron nanoparticles. The sub-micron nanoparticles formation has been successfully achieved by the use of novel nano spray techniques.

Abstract: The present invention relates to a poly(lactic glycolic) acid (PLGA) nanoparticle associated with therapeutic agents for a variety of therapeutic applications.

Abstract: The present invention makes use of a unique methodology of double nano-encapsulation for protecting and controlling the release of active agents, either hydrophobic or hydrophilic, from stable nanoparticles of opposite characteristics. The protection of the active agent was achieved by loading the agent to be protected, into nanocarriers, which were subsequently encapsulated into sub-micron nanoparticles. The sub-micron nanoparticles formation has been successfully achieved by the use of novel nano spray techniques.

Abstract: The present invention relates to a poly(lactic glycolic) acid (PLGA) nanoparticle associated with therapeutic agents for a variety of therapeutic applications.

Abstract: On one hand, the present invention relates to cosmetic compositions comprising poly(lactic glycolic)acid (PLGA) nanoparticles for applications to the skin. On the other hand, it also concerns polymeric nanoparticles having on its surface a plurality of cosmetically active agents, each of said agents being associated to said nanoparticle via oleylcysteineamide, delivery systems for topical application based on said particles and cosmetic formulations comprising said particles.